Nasdepi®
Emergency treatment of severe allergic reactions (Type I) including anaphylaxis
Clinical trials (phase unspecified)Active
Key Facts
Indication
Emergency treatment of severe allergic reactions (Type I) including anaphylaxis
Phase
Clinical trials (phase unspecified)
Status
Active
Company
About Belhaven Biopharma
Belhaven Biopharma is a private, pre-revenue biotech developing Nasdepi®, a novel dry powder epinephrine nasal spray for the emergency treatment of anaphylaxis. Currently in clinical trials, the product aims to address significant shortcomings of existing epinephrine auto-injectors, including needle phobia, poor global access, and sensitivity to extreme temperatures. The company is targeting a large and underserved global market of individuals at risk for severe allergic reactions, with a value proposition centered on accessibility, ease of use, and stability.
View full company profile